Clinical Trial Update: ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

View source ↗

Summary

This ClinicalTrials.gov entry describes an observational study evaluating Omlyclo®, an omalizumab biosimilar, in patients with chronic spontaneous urticaria and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma
• Spontaneous Urticaria

Drugs mentioned

• Omlyclo® (omalizumab biosimilar)

Snippet

Sponsor: Celltrion HealthCare France | Conditions: Chronic Spontaneous Urticaria (CSU), Allergic Asthma | Status: RECRUITING